Savant Capital LLC Decreases Position in Alnylam Pharmaceuticals, Inc. $ALNY

Savant Capital LLC lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 3,766 shares of the biopharmaceutical company’s stock after selling 12,825 shares during the quarter. Savant Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $1,228,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Teacher Retirement System of Texas boosted its stake in shares of Alnylam Pharmaceuticals by 3.2% in the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after purchasing an additional 1,123 shares during the period. Envestnet Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 33.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock worth $31,238,000 after buying an additional 23,749 shares during the period. Simon Quick Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $222,000. Strs Ohio purchased a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $7,781,000. Finally, Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target on the stock. Citigroup upped their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $452.74 on Thursday. The stock’s 50 day simple moving average is $458.85 and its 200 day simple moving average is $381.24. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a market cap of $59.81 billion, a P/E ratio of -183.30 and a beta of 0.30. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $1.39 by $1.51. The firm had revenue of $1.25 billion during the quarter, compared to analyst estimates of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s revenue for the quarter was up 149.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the sale, the executive vice president owned 27,438 shares in the company, valued at $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president directly owned 25,231 shares in the company, valued at $11,405,673.55. This represents a 8.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 66,696 shares of company stock worth $30,430,694. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.